Trials and Noteworthy Treatments

News Stories

(Relevance) Question - click to see the response!
Displaying 1 to 18 of 18
Click HERE for Next 25 articles!

(Relevance) Page Title - click title to go to the page!

•   (0.8792)   FDA Advisory Committee Does Not Recommend Approval of RSR13 as Adjunctive Therapy for the Treatment of Brain Metastases Originating From Breast Cancer
  
  
•   (0.8510)   Allos Therapeutics Completes Patient Enrollment in Pivotal Phase 3 Study of Efaproxyn in Women with Brain Metastases Originating from Breast Cancer
  
  
•   (0.8169)   Results Published in Journal of Clinical Oncology Affirm Survival Benefit of EFAPROXYN(TM) in Patients with Brain Metastases Originating From Breast Cancer
  
  
•   (0.8164)   Neurospheres Enriched in Cancer Stem-Like Cells Are Highly Effective in Eliciting a Dendritic Cell-Mediated Immune Response against Malignant Gliomas.
  
  
•   (0.7967)   Drug that can fight brain cancer discovered
  
  
•   (0.7967)   Allos` brain cancer drug flops in phase 3
  
  
•   (0.7967)   Survival benefit confirmed in patients with brain metastases from breast cancer
  
  
•   (0.7967)   Updated Results of Allos` Phase 3 Reach Study Confirm Survival Benefit in Patients With Brain Metastases From Breast Cancer
  
  
•   (0.7742)   Allos brain tumor trial gets clearance to continue
  
  
•   (0.7742)   Tumor Necrosis Factor-{alpha}-Induced Protein 3 As a Putative Regulator of Nuclear Factor-{kappa}B-Mediated Resistance to O6-Alkylating Agents in Human Glioblastomas.
  
  
•   (0.7742)   Xenova Group plc -- TransMID Obtains Orphan Drug Designation in Japan
  
  
•   (0.7742)   Thymic function and output of recent thymic emigrant T cells during intracranial glioma progression.
  
  
•   (0.7742)   Why the Republicans want to be governor (Daily Herald)
  ... cases of cancer came the sudden death of his 12-year-old daughter Annie from an undiagnosed brain tumor, and the near-death of wife Marie from a mysterious virus that initially appeared to...
  - Mar 06 8:23 AM ET
  
  
•   (0.7742)   Prognostic Factors Influencing Survival in Patients with Brain Metastases Identified in Largest Ever Randomized Study
  
  
•   (0.7742)   TransMolecular Names Randall B. Riggs Vice President, Business Development
  
  
•   (0.7742)   Abstracts on Allos Therapeutics` RSR13 to Be Presented at American Society of Clinical Oncology Annual Meeting
  
  
•   (0.7742)   Gene Research Raises Fears of Discrimination (Reuters)
  ... hamper research efforts to cure illnesses such as cancer or heart disease....... body the human genome resides, one-third said the brain,...
  - Jun 27 7:07 PM ET
  
  
•   (0.7742)   Pharmos Reports Progress in Dexanabinol Program (PR Newswire)
  Pharmos Corporation presented today the results of its entire Phase II clinical trial for dexanabinol in the treatment of traumatic brain injury at the Eleventh International Symposium on Intracranial Pressure and Brain Monitoring in Cambridge, England.
  - Jul 26 10:19 AM ET
  
  

Frequently Asked Questions